PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12526535

Cyclotriphosphorus complexes: solid-state structures and dynamic behavior of monoadducts with carbonyl fragments.

M Di Vaira·M P Ehses·P Stoppioni·M Peruzzini
View original source ↗Export metadata ↓

Abstract

Treatment of the cyclo-P3 complexes [(triphos)MP3] [triphos = 1,1,1-tris(diphenylphosphinomethyl)ethane; M = Co (1), Rh (2)] with stoichiometric amounts of [M'(CO)5(thf)]n+ (n = 0, M' = Cr, Mo, W; n = 1, M' = Re) and [W(CO)4(PPh3)(thf)] yields the compounds [[(triphos)M](mu,eta 3:1-P3) [M'(CO)5]] [M = Co; M' = Cr (3a), Mo (3b), W (3c). M = Rh; M' = W (4)], [[(triphos)Co](mu,eta 3:1-P3)[Re(CO5)]]BF4.C7H8 (5) and [[(triphos)Rh](mu,eta 3:1-P3)[W(CO)4PPh3]].2CH2Cl2 (6). The X-ray structures of 5 and 6 have been determined. Crystal data: 5, monoclinic space group P2(1)/n, a = 14.754(2) A, b = 24.886(4) A, c = 15.182(2) A, beta = 103.38(1) degrees, Z = 4; 6, monoclinic space group P2(1)/n, a = 14.872(3) A, b = 27.317(6) A, c = 16.992(4) A, beta = 111.75(5) degrees, Z = 4. The effects of eta 1 coordination on the MP3 core are discussed by comparing the MP3 skeletons in the above structures with those of the previously characterized bis and tris end-on adducts of organometallic fragments of 1. Variable temperature NMR data for the compounds provide evidence for fluxional processes in solution that may be interpreted as [(triphos)M] rotation about its C3 axis and [M'(CO)5] or [M'(CO)4PPh3] scrambling over the P3 cycle. The activation parameters of the fragment scrambling process are determined.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Di Vaira, M P Ehses, P Stoppioni, M Peruzzini. 2000-05-15. Cyclotriphosphorus complexes: solid-state structures and dynamic behavior of monoadducts with carbonyl fragments.. https://doi.org/10.1021/ic991380w

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗